Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While PEG-MGF is used experimentally to enhance muscle repair and hypertrophy after mechanical overload or injury by stimulating satellite-cell activation and protein synthesis6373138, Retatrutide is an investigational agent that produces very large body-weight reductions in early trials by simultaneously engaging GLP-1R, GIPR, and GCGR to enhance satiety, energy expenditure, and glycemic control2575.
While PEG-MGF works as a poly(ethylene glycol)-conjugated form of Mechano Growth Factor (IGF-1Ec splice variant) comprising the 24-aa C-terminal E-peptide of IGF-1, designed to extend half-life while activating IGF-1 receptor–mediated anabolic signaling in muscle satellite cells637322138, Retatrutide is a triple incretin agonist peptide derived from a GIP backbone and engineered to activate GLP-1, GIP, and glucagon receptors, with non-natural residues and fatty-acid conjugation that confer long half-life and balanced multi-receptor signaling256575.
PEG-MGF
IGF1
Retatrutide
Not assigned in the current dataset.
PEG-MGF and Retatrutide are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: PEG-MGF is more often discussed in the realm of Musculoskeletal health and Cardiovascular health, whereas Retatrutide is more often associated with the realm of Metabolic and endocrine. Their biological logic is quite different: PEG-MGF is a growth factor mimetic and a signaling modulator, whereas Retatrutide is a receptor agonist and a hormone analog. Both are synthetic in origin with PEG-MGF in Preclinical development and Retatrutide in Clinical phase 3. PEG-MGF carries pegylation features, while Retatrutide instead reflects lipidation changes, while their sequence patterns also diverge, with PEG-MGF showing protein-mimetic sequence features and Retatrutide showing alpha-helical domain features.